BOSTON, Feb. 25 /PRNewswire-FirstCall/ -- Experts from PAREXEL
International Corporation (Nasdaq: PRXL), a leading global
bio/pharmaceutical services provider, will present on key topics at the
Drug Information Association's (DIA) 20th Annual EuroMeeting in Barcelona,
Spain being held March 3 - 5, 2008. Attendees will benefit from
presentations by some of PAREXEL's thought leaders, selected by the DIA to
address industry issues including pharmacovigilance, globalization of
clinical trials, data-driven patient recruitment, non-interventional
studies, gene therapy regulations, combination products, biosimilars, and
PAREXEL experts will present or chair the following sessions:
Monday, March 3
-- Pharmacovigilance and Medical Writing View With Emphasis on Practical
Solutions to the Pitfalls and Grey Areas (tutorial) - Alison Rapley,
Director, Medical Writing Services, Europe, Clinical Research Services
-- Navigating the Gene Therapy Regulations for Clinical Trials -- Cecil
Nick, Principal Consultant, PAREXEL Consulting
Tuesday, March 4
-- Globalization of Clinical Trials: Opportunities and Risks -- Session
Chair: Alberto Grignolo, Ph.D., Corporate Vice President and General
Manager, PAREXEL Consulting
-- Combination Products: Drug or Device? -- Cecil Nick, Principal
Consultant, PAREXEL Consulting
-- Data Driven Patient Recruitment: Tools for Early Planning and
Predictive Management (poster presentation) -- Petra Moll, Associate
Director, Clinical Operations, Clinical Research Services
Wednesday, March 5
-- Meeting Patient Enrollment Targets for Non-Interventional Studies --
Gary Coward, Senior Director, Peri-Approval Clinical Excellence,
Clinical Research Services
-- Biosimilars: What Should the Next Steps Be? -- Session Co-Chair: Cecil
Nick, Principal Consultant, PAREXEL Consulting
-- Cosmeceuticals: Marketing Topical Products without Making Licensable
Medicinal Claims in Europe -- Peter Lassoff, Vice President, PAREXEL
For more than 25 years, clients have relied on PAREXEL to provide integrated clinical development, regulatory affairs consulting, and commercialization services, as well as to offer technologies that expedite time-to-market. Attendees at the DIA EuroMeeting can visit PAREXEL's Booth 179 in the exhibit hall to discuss these areas or to view a demonstration of the industry-leading Clinical Trial Management System IMPACT(R) software, provided by PAREXEL's subsidiary, Perceptive Informatics.
DIA's 20th Annual EuroMeeting is global in scope, attracting more than 3,000 attendees. This meeting brings together professionals from the biopharmaceutical industry, contract service organizations, academic research centers, and regulatory agencies. With more than 100 sessions and 11 themes, and more than 350 speakers, the annual event covers a variety of cross- disciplinary topics.
For more information about PAREXEL visit http://www.PAREXEL.com or Booth 179 at the DIA EuroMeeting.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements
should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL and IMPACT are registered trademarks of PAREXEL International
Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of
Perceptive Informatics, Inc. All other names or marks may be registered
trademarks or trademarks of their respective business and are hereby
Jennifer Baird, Director of Public Relations
|SOURCE PAREXEL International Corporation|
Copyright©2008 PR Newswire.
All rights reserved